Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 12/20 | 0.83 |
| ▸ | NPC1 | O15118 | 11/20 | 0.83 |
| ▸ | SMN1; SMN2 | Q16637 | 7/20 | 0.83 |
| ▸ | TP53 | P04637 | 5/20 | 0.83 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.83 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.73 |
| ▸ | MEN1 | O00255 | 3/20 | 0.73 |
| ▸ | LMNA | P02545 | 3/20 | 0.73 |
| ▸ | POLB | P06746 | 2/20 | 0.73 |
| ▸ | PKM | P14618 | 2/20 | 0.73 |
| ▸ | APEX1 | P27695 | 1/20 | 0.73 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.73 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.68 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.68 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.68 |
| ▸ | GAA | P10253 | 2/20 | 0.66 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.66 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.66 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.66 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11462217 | 1.00 | RAB9A (0.83) | RAB9ANPC1SMN1; SMN2TP53ALOX15 | |
| SCHEMBL6799157 | 0.91 | RAB9A (1.00) | RAB9ANPC1SMN1; SMN2TP53ALOX15 | |
| SCHEMBL10016092 | 0.91 | RAB9A (0.69) | RAB9ANPC1SMN1; SMN2TP53ALOX15 | |
| SCHEMBL5501099 | 0.88 | ALOX5 (0.68) | RAB9ANPC1SMN1; SMN2TP53ALOX15 | |
| SCHEMBL14490986 | 0.87 | RAB9A (0.83) | RAB9ANPC1SMN1; SMN2TP53ALOX15 | |
| SCHEMBL15580882 | 0.86 | NPC1 (0.74) | RAB9ANPC1SMN1; SMN2TP53ALOX15 | |
| SCHEMBL8769709 | 0.86 | RAB9A (0.89) | RAB9ANPC1SMN1; SMN2TP53ALOX15 | |
| SCHEMBL22192206 | 0.86 | RAB9A (0.89) | RAB9ANPC1SMN1; SMN2TP53ALOX15 | |
| SCHEMBL8771228 | 0.86 | POLB (0.79) | RAB9ANPC1SMN1; SMN2TP53ALOX15 | |
| SCHEMBL22694283 | 0.86 | POLB (0.79) | RAB9ANPC1SMN1; SMN2TP53ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108530444-B | Novel NAMPT and IDO dual inhibitor and preparation method and medical application thereof | 药康众拓(江苏)医药科技有限公司 | 2021-08-24 | — | — | CN | disclosed |
| US-11078165-B2 | Compounds for treating tuberculosis | NANYANG TECHNOLOGICAL UNIVERSITY (SG) | 2021-08-03 | — | — | US | disclosed |
| US-11078165-B2 | Compounds for treating tuberculosis | NANYANG TECHNOLOGICAL UNIVERSITY (SG) | 2021-08-03 | — | — | US | disclosed |
| US-20200231550-A1 | COMPOUNDS FOR TREATING TUBERCULOSIS | NANYANG TECHNOLOGICAL UNIVERSITY (SG) | 2020-07-23 | — | — | US | disclosed |
| US-20200231550-A1 | COMPOUNDS FOR TREATING TUBERCULOSIS | NANYANG TECHNOLOGICAL UNIVERSITY (SG) | 2020-07-23 | — | — | US | disclosed |
| US-10538485-B2 | Compounds for use as therapeutic agents affecting P53 expression and/or activity | ABIVAX (FR) | 2020-01-21 | — | — | US | disclosed |
| CN-110520412-A | Compounds for the treatment of tuberculosis | UNIV NANYANG TECH | 2019-11-29 | — | — | CN | disclosed |
| CN-105884699-B | 4- substituted aniline quinazoline derivative and its preparation method and application | 中国药科大学 | 2019-05-07 | — | — | CN | disclosed |
| CN-108530444-A | A kind of novel NAMPT and IDO double inhibitors and preparation method thereof and medical usage | 中国药科大学 | 2018-09-14 | — | — | CN | disclosed |
| US-20180127353-A1 | COMPOUNDS FOR USE AS THERAPEUTIC AGENTS AFFECTING P53 EXPRESSION AND/OR ACTIVITY | ABIVAX (FR) | 2018-05-10 | — | — | US | disclosed |
| US-6255349-B1 | PREVENTION REPRODUCTION; VIRICIDES | AMERICAN HOME PRODUCTS CORPORATION | 2001-07-03 | — | — | US | disclosed |
| US-6207715-B1 | USEFUL IN THERAPY OF DISEASES ASSOCIATED WITH HERPES VIRUSES INCLUDING HUMAN CYTOMEGALOVIRUS, HERPES SIMPLEX VIRUSES, EPSTEIN-BARR VIRUS, VARICELLA-ZOSTER VIRUS, HUMAN HERPESVIRUSES-6 AND -7, AND KAPOSI HERPES VIRUS | AMERICAN HOME PRODUCTS CORPORATION | 2001-03-27 | — | — | US | disclosed |
| US-6201013-B1 | INOSINE MONOPHOSPHATE DEHYDROGENASE (IMPDH) INHIBITOR; SIDE EFFECT REDUCTION, NON-DRUG RESISTANT | AMERICAN HOME PRODUCTS CORPORATION | 2001-03-13 | — | — | US | disclosed |
| US-6197803-B1 | VIRICIDES; PREVENTION REPRODUCTION | AMERICAN HOME PRODUCTS CORPORATION | 2001-03-06 | — | — | US | disclosed |
| US-6166028-A | Diaminopuridine-containing thiourea inhibitors of herpes viruses | AMERICAN HOME PRODUCTS CORPORATION (US) | 2000-12-26 | — | — | US | disclosed |
| WO-2000034261-A2 | HETEROCYCLIC CARBOXAMIDE-CONTAINING THIOUREA INHIBITORS OF HERPES VIRUSES CONTAINING A SUBSTITUTED PHENYLENEDIAMINE GROUP | AMERICAN HOME PRODUCTS CORPORATION (US) | 2000-06-15 | — | — | WO | disclosed |
| WO-2000034260-A2 | ALPHA-METHYLBENZYL-CONTAINING THIOUREA INHIBITORS OF HERPES VIRUSES CONTAINING A PHENYLENEDIAMINE GROUP | AMERICAN HOME PRODUCTS CORPORATION (US) | 2000-06-15 | — | — | WO | disclosed |
| WO-2000034238-A1 | THIOUREA INHIBITORS OF HERPES VIRUSES | AMERICAN HOME PRODUCTS CORPORATION (US) | 2000-06-15 | — | — | WO | disclosed |
| WO-2000034237-A2 | ACETAMIDE AND SUBSTITUTED ACETAMIDE-CONTAINING THIOUREA INHIBITORS OF HERPES VIRUSES | AMERICAN HOME PRODUCTS CORPORATION (US) | 2000-06-15 | — | — | WO | disclosed |
| WO-2000034258-A2 | HETEROCYCLIC CARBOXAMIDE-CONTAINING THIOUREA INHIBITORS OF HERPES VIRUSES CONTAINING PHENYLENEDIAMINE GROUP | AMERICAN HOME PRODUCTS CORPORATION (US) | 2000-06-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11078165-B2 | Compounds for treating tuberculosis | ATP5ME, ATP5MG, ATP5F1D | RAB9A 2809/4885NPC1 1580/4885SMN1; SMN2 4805/4885 |
| US-20180127353-A1 | COMPOUNDS FOR USE AS THERAPEUTIC AGENTS AFFECTING P53 EXPRESSION AND/OR ACTIVITY | TP53, TP53BP1, BCOR | RAB9A 615/4885NPC1 2190/4885SMN1; SMN2 2920/4885 |
| US-10538485-B2 | Compounds for use as therapeutic agents affecting P53 expression and/or activity | TP53, TP53BP1, BCOR | RAB9A 615/4885NPC1 2190/4885SMN1; SMN2 2920/4885 |
| US-20200231550-A1 | COMPOUNDS FOR TREATING TUBERCULOSIS | ATP5ME, ATP5MG, ATP5F1D | RAB9A 2809/4885NPC1 1580/4885SMN1; SMN2 4805/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.